Work

Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33849-7

Authors: M. Kris, Z. Goldberg, P.A. Janne, D. Kim, R. Martins, T.S.K. Mok, J. O'Connell, S. Ou, I. Taylor, H. Zhang

Institutions: Memorial Sloan Kettering Cancer Center, Pfizer (United States), Dana-Farber Cancer Institute, Seoul National University Hospital, Seattle Cancer Care Alliance, University of Washington, Chinese University of Hong Kong, Prince of Wales Hospital, University of California, Irvine, University of California, Irvine Medical Center, Pfizer (China)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2998961111

FWCI: 4.991

Cites:

Cited by: 22

Related to: 10